Digital Therapeutics as Standard Care
In 2026, Germany's Digitale Gesundheitsanwendungen (DiGA) program has entered a new phase of expansion. Statutory health insurance providers (Krankenkasse) like TK and AOK now fully reimburse a wider range of 'Class IIb' medical device apps, including those for advanced diabetes management and mental health support. These apps are 'prescribed' by your doctor just like medication. Once you receive your prescription, you provide it to your insurer, who then sends an activation code. This system ensures that every German resident has access to evidence-based behavioral tech to manage metabolic conditions and optimize heart health without out-of-pocket costs.
Performance-Based Pricing in German Health Tech
A major shift in 2026 is the introduction of performance-based pricing for DiGAs. Manufacturers must now demonstrate real-world positive healthcare effects—such as a sustained reduction in HbA1c or improved quality of life—to maintain their reimbursement levels. This ensures that the digital tools German patients use are not just innovative, but clinically effective for long-term chronic disease management.
Measuring DiGA Impact
The clinical efficacy of a DiGA is often measured by the Absolute Risk Reduction (ARR) of secondary complications in its user base.
Absolute Risk Reduction (ARR) Formula
Where $CER$ is the Control Event Rate and $EER$ is the Experimental Event Rate. Apps that show a high ARR for metabolic events are prioritized in the BfArM directory and highly recommended by German clinicians.
Accessing Your Digital Benefits
For German professionals, these apps offer a convenient way to manage health amidst a busy schedule. Strategic Advice: When visiting your 'Hausarzt,' ask for the 'DiGA-Verzeichnis' and see which apps match your diagnosis (e.g., F32 for depression or E11 for diabetes). Many Krankenkassen also offer additional bonuses for active use of these apps. Combining a DiGA for nutritional tracking with a TGA-approved biomarker monitoring strategy creates a robust shield against the metabolic dysfunction that leads to heart disease and NASH.